0001104659-22-057537.txt : 20220509
0001104659-22-057537.hdr.sgml : 20220509
20220509161759
ACCESSION NUMBER: 0001104659-22-057537
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220506
FILED AS OF DATE: 20220509
DATE AS OF CHANGE: 20220509
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Leider Harry L.
CENTRAL INDEX KEY: 0001888273
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39362
FILM NUMBER: 22905220
MAIL ADDRESS:
STREET 1: C/O GELESIS, INC.
STREET 2: 501 BOYLSTON STREET, SUITE 6102
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GELESIS HOLDINGS, INC.
CENTRAL INDEX KEY: 0001805087
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 844730610
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 BOYLSTON STREET, SUITE 6102
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 857-327-7737
MAIL ADDRESS:
STREET 1: 501 BOYLSTON STREET, SUITE 6102
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: CAPSTAR SPECIAL PURPOSE ACQUISITION CORP.
DATE OF NAME CHANGE: 20200227
4
1
tm2214815d8_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-05-06
0
0001805087
GELESIS HOLDINGS, INC.
GLS
0001888273
Leider Harry L.
GELESIS HOLDINGS, INC.
501 BOYLSTON STREET, SUITE 6102
BOSTON
MA
02116
0
1
0
0
Chief Medical Officer
Common Stock
2022-05-06
4
A
0
10164
A
10164
D
Common Stock
2022-05-06
4
A
0
34266
A
44430
D
Common Stock
2022-05-06
4
A
0
269660
A
314090
D
Stock Option (Right to Buy)
3.33
2022-05-06
4
A
0
269660
0
A
2032-03-03
Common Stock
269660
269660
D
Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement.
These RSUs vest in full on February 8, 2023, subject to the reporting person's continued service at such time.
These RSUs vest in full on February 15, 2023, subject to the reporting person's continued service at such time.
25% of these RSUs shall vest on April 1, 2023, with the remainder vesting in twelve (12) equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date.
25% of the shares underlying this option shall vest and become exercisable on March 4, 2023, with the remainder vesting in twelve (12) equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date.
/s/ David Abraham, Attorney-in-Fact
2022-05-09